"Modulus ALIF has been one of NuVasive's most successful clinical evaluations to date with continued surgeon adoption and overwhelmingly positive feedback. This differentiated technology furthers our position to become the market leader in ALIF and extends our Modulus portfolio across all procedural segments," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive. "We are leveraging our experience as the leader in lateral surgery to deliver outcome-driven innovation to fuel continued growth and differentiation in the anterior spine segment."